The impact of hepatitis C virus coinfection on HIV-related kidney disease: A systematic review and meta-analysis

AIDS

Volumn 22, Issue 14, 2008, Pages 1799-1807

  Wyatt, Christina M ^a   Malvestutto, Carlos ^a   Coca, Steven G ^b   Klotman, Paul E ^a   Parikh, Chirag R ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C; Hepatitis coinfection; HIV; Kidney disease; Nephrotoxicity

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; TENOFOVIR;

ACUTE KIDNEY FAILURE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; GENETIC HETEROGENEITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; META ANALYSIS; MIXED INFECTION; MORBIDITY; MORTALITY; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; RISK FACTOR; SYSTEMATIC REVIEW;

ACUTE KIDNEY INJURY; AFRICAN CONTINENTAL ANCESTRY GROUP; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RISK;

EID: 66349107162     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830e0152     Document Type: Article

References (57)

1. UNAIDS. UNAIDS/WHO AIDS Epidemic Update: December 2006; 2006.
2. SelikRM, ByersRHJr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29:378-387.
3. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antire-troviral treatment. N EnglJ Med 2006; 355:2283-2296.
4. U.S. Renal Data System. USRDS 2007 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States; 2007.
5. Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, Moore RD. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative subjects followed between 1988 and 2004. AIDS 2007; 21:2435-2443.
6. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'hare AM. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J AmSoc Nephrol 2007; 18:2968-2974.
7. Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome- associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14:377-383.
8. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIVR end-stage renal disease. J Am Soc Nephrol 2005; 16:2412-2420.
9. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585.
10. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
11. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. I Hepatol 2006; 44:S6-S9.
12. Graham CS, Baden LR, Yu E, MrusJM, CarnieJ, HeerenT, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
13. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare AM. Association of hepatitis C seropo-sitivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167:1271-1276.
14. Tsui JI, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. I Am Soc Nephrol 2006; 17:1168-1174.
15. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure amongwomenwithHIVinfection. Kidney Int 2002; 61:195-202.
16. Franceschini N, Napravnik S, Eron JJJ, Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67:1526-1531.
17. Gupta SK,MamlinBW, Johnson CS, DollinsMD,Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004; 61:1-6.
18. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36:363-367.
19. Isnard Bagnis C, Tezenas Du Montcel S, Fonfrede M, Jaudon MC, Thibault V, Carcelain G, et al. Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol 2006; 103:131-138.
20. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21:1119-1127.
21. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465-470.
22. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, MellorJ, Ben Yahia MB, Andre C, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122:169-173.
23. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184.
24. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133:592-599.
25. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840-848.
26. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324:342-344.
27. Willson RA. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastroenterol 2002; 35:89-92.
28. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
29. KuoG, ChooQL, Alter HJ, GitnickGL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362-364.
30. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144:427-437.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327:557-560.
33. Ahuja TS, Borucki M, Funtanilla M, Shahinian V, Hollander M, Rajaraman S. Is the prevalence of HIV-associated nephropathy decreasing? Am J Nephrol 1999; 19:655-659.
34. Becker S, Fusco G, Fusco J, Balu R, Gangjee S, Brennan C, FeinbergJ. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39 (Suppl 5):S267-S275.
35. Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998; 12:2433-2437.
36. Dieleman JP, van Rossum AM, Stricker BC, Sturkenboom MC, de Groot R, Telgt D, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr 2003; 32:135-142.
37. Duval X, Journot V, Leport C, Chene G, Dupon M, Cuzin L, et al. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. Clin Infect Dis 2004; 39:248-255.
38. Franceschini N, Napravnik S, Finn WF, Szczech LA, Eron JJJ. Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 42:368-372.
39. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198.
40. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CC, Rompalo AM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:203-209.
41. Gardner LI, Klein RS, Szczech LA, Phelps RM, Tashima K, Rompalo AM, et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 2003; 34:320-330.
42. Jung O, Bickel M, Ditting T, Rickerts V, Welk T, Helm EB, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant 2004; 19:2250-2258.
43. Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI, McGwin GJ. Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS 2004; 18:2171-2178.
44. Kulkarni R, SoucieJM, Evatt B. Renal disease among males with haemophilia. Haemophilia 2003; 9:703-710.
45. Lopes JA, Fernandes J, Jorge S, Neves J, Antunes F, Prata MM. Acute renal failure in critically ill HIV-infected patients. Crit Care 2007; 11:404.
46. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546.
47. Malavaud B, Dinh B, Bonnet E, Izopet J, Payen JL, Marchou B. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 2000; 5:3-5.
48. Meraviglia P, Angel i E, Del Sorbo F, Rombola G, Vigano P, Orlando G, et al. Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS 2002; 16:2089-2093.
49. Padilla S, Gutierrez F, Masia M, Canovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 2005; 19:421-424.
50. ReislerRB, Han C, Burman WJ, Tedaldi EM, NeatonJD. Grade4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34:379-386.
51. Shahinian V, Rajaraman S, Borucki M, GradyJ, Hollander WM, Ahuja TS. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000; 35:884-888.
52. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145-1152.
53. Szczech LA, Grunfeld C, Scherzer R, CancholaJA, van der Horst C, Sidney S, et al. Microalbuminuria in HIV infection. AIDS 2007; 21:1003-1009.
54. Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, Emery S. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006; 7:105-111.
55. WHO. World Health Organization Media Centre: Hepatitis C (Fact sheet No 146). World Health Organization Media Centre; 2000.
56. Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, Cohen AJ, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007; 21:2101-2103.
57. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20:561-565.